CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 20 enrolled
Drug / intervention
AZD2927 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01396226
NCT01396226Phase 2Completed

A Multi-Centre, Double-Blind, Randomised, Placebo-Controlled Phase II Study to Assess the Effects on Atrial and Ventricular Refractoriness of an Intravenous Infusion of AZD2927 in Patients Undergoing an Invasive Electrophysiological Procedure

AstraZeneca·interventional·Posted Jul 18, 2011·Updated Nov 27, 2012

In Brief

A Phase 2 clinical trial evaluating AZD2927 and Placebo for Arrhythmia. Completed, enrolled 20 participants across 5 sites in 2 countries.

Detailed Summary

Medical Products Agency

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsArrhythmia
CountriesNorway, Sweden
Collaborators--

Timeline

Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedJul 18, 2011
Enrollment StartSep 1, 2011
Primary CompletionJan 1, 2012
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 15.0 years ago

Interventions

AZD2927drug

A single dose of AZD2927 administered as an iv infusion

Placebodrug

A single dose of placebo administered as an iv infusion